NO20001514D0 - Vitronectin-reseptor-antagonist - Google Patents

Vitronectin-reseptor-antagonist

Info

Publication number
NO20001514D0
NO20001514D0 NO20001514A NO20001514A NO20001514D0 NO 20001514 D0 NO20001514 D0 NO 20001514D0 NO 20001514 A NO20001514 A NO 20001514A NO 20001514 A NO20001514 A NO 20001514A NO 20001514 D0 NO20001514 D0 NO 20001514D0
Authority
NO
Norway
Prior art keywords
receptor antagonist
vitronectin receptor
vitronectin
antagonist
receptor
Prior art date
Application number
NO20001514A
Other languages
English (en)
Other versions
NO20001514L (no
Inventor
Dirk Andries Heerding
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20001514L publication Critical patent/NO20001514L/no
Publication of NO20001514D0 publication Critical patent/NO20001514D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20001514A 1997-09-24 2000-03-23 Vitronectin-reseptor-antagonist NO20001514D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5983297P 1997-09-24 1997-09-24
PCT/US1998/019949 WO1999015170A1 (en) 1997-09-24 1998-09-24 Vitronectin receptor antagonist

Publications (2)

Publication Number Publication Date
NO20001514L NO20001514L (no) 2000-03-23
NO20001514D0 true NO20001514D0 (no) 2000-03-23

Family

ID=22025570

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20001514A NO20001514D0 (no) 1997-09-24 2000-03-23 Vitronectin-reseptor-antagonist

Country Status (13)

Country Link
EP (1) EP1017387A4 (no)
JP (1) JP2002528380A (no)
KR (1) KR20010024247A (no)
CN (1) CN1273529A (no)
AU (1) AU9577498A (no)
BR (1) BR9813208A (no)
CA (1) CA2303846A1 (no)
HU (1) HUP0003949A2 (no)
IL (1) IL135189A0 (no)
NO (1) NO20001514D0 (no)
PL (1) PL339413A1 (no)
TR (1) TR200000792T2 (no)
WO (1) WO1999015170A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2358855A1 (en) 1999-02-03 2000-08-10 Merck & Co., Inc. Benzazepine derivatives as alpha-v integrin receptor antagonists
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
CA2419255A1 (en) * 2000-08-29 2002-03-07 Ish Kumar Khanna Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists
AU2001288515A1 (en) * 2000-08-30 2002-03-13 Pharmacia Corporation Gem-substituted alpha v beta 3 integrin antagonists
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
EP1381384B1 (en) 2001-04-24 2011-05-25 Merck Patent GmbH COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
CA2464472C (en) 2001-10-22 2014-01-07 The Scripps Research Institute Antibody targeting compounds
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2007084670A2 (en) 2006-01-18 2007-07-26 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
KR20090108713A (ko) 2007-01-18 2009-10-16 메르크 파텐트 게엠베하 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약
US8377922B2 (en) 2007-11-16 2013-02-19 Ube Industries, Ltd. Benzazepinone compound
EP2257538B1 (en) * 2008-03-06 2016-04-27 GlaxoSmithKline LLC Process for the preparation of benzodiazepine derivatives
EP2395992A2 (en) 2009-02-10 2011-12-21 The Scripps Research Institute Chemically programmed vaccination
JPWO2010113958A1 (ja) 2009-03-30 2012-10-11 宇部興産株式会社 眼の疾患の治療又は予防のための医薬組成物
JP5572996B2 (ja) * 2009-05-15 2014-08-20 宇部興産株式会社 ベンズアゼピノン化合物を有効成分として含有する医薬
SG176103A1 (en) 2009-05-25 2011-12-29 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
CN103864765B (zh) * 2014-03-05 2016-02-10 天津药物研究院 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途
MX2016015467A (es) 2014-05-30 2017-03-23 Pfizer Derivados de carbonitrilo como moduladores selectivos del receptor de androgenos.
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0762882A4 (en) * 1994-06-29 2002-09-11 Smithkline Beecham Corp Vibronectin Receptor Antagonists
UA60311C2 (uk) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
EP0946180A4 (en) * 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION

Also Published As

Publication number Publication date
NO20001514L (no) 2000-03-23
JP2002528380A (ja) 2002-09-03
EP1017387A1 (en) 2000-07-12
PL339413A1 (en) 2000-12-18
CN1273529A (zh) 2000-11-15
WO1999015170A1 (en) 1999-04-01
IL135189A0 (en) 2001-05-20
HUP0003949A2 (hu) 2001-10-28
AU9577498A (en) 1999-04-12
EP1017387A4 (en) 2004-08-18
BR9813208A (pt) 2000-08-22
CA2303846A1 (en) 1999-04-01
KR20010024247A (ko) 2001-03-26
TR200000792T2 (tr) 2000-09-21

Similar Documents

Publication Publication Date Title
BR9712248A (pt) Antagonista receptores de vitronectina
NO965608D0 (no) Vitronectin-reseptor-antagonister
NO993350D0 (no) Vitronectin-reseptor-antagonister
NO983001D0 (no) Vitronectin-reseptor-antagonister
NO983003D0 (no) Vitronectin-reseptor-antagonister
NO983002D0 (no) Vitronectin-reseptor-antagonister
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
EP1000031A4 (en) VITRONECTIN RECEPTOR ANTAGONISTS
NO20001100D0 (no) IL-8 reseptorantagonister
NO20001514D0 (no) Vitronectin-reseptor-antagonist
NO20001515D0 (no) Vitronektin reseptor-antagonist
NO20004503L (no) Vitronectin-reseptor-antagonister
NO20001407D0 (no) Vitronectin-reseptor-antagonister
ID24726A (id) Antagonis-antagonis reseptor trombin
ATE381330T1 (de) Il-8 rezeptor-antagonisten
DE69920518D1 (de) Vitronectin rezeptor antagonist
ATE303370T1 (de) Il-8 rezeptor antagonisten
DE69824837D1 (de) Il-8-rezeptor-antagonisten
NO20021113D0 (no) Vitronectin-reseptor-antagonister
NO20010620D0 (no) Vitronektinreseptor-antagonister
DE69830671D1 (de) Integrin-rezeptor-antagonisten
DK1218005T3 (da) Vitronectinreptorantagonister

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application